Proteasome inhibitor patents (2010 - present). (Q35085938)

6 August 2017

title

Proteasome inhibitor patents (2010 - present). (English)

1 reference

6 August 2017

0 references

Rainer Metcalf

1 reference

6 August 2017

Latanya M Scott

series ordinal

1 reference

6 August 2017

Kenyon G Daniel

series ordinal

1 reference

6 August 2017

Q Ping Dou

series ordinal

1 reference

6 August 2017

language of work or name

English

0 references

publication date

23 January 2014

1 reference

Expert Opinion on Therapeutic Patents

6 August 2017

published in

1 reference

6 August 2017

1 reference

6 August 2017

1 reference

6 August 2017

page(s)

369-382

1 reference

Proteolysis: The proteasome: a protein-degrading organelle?

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877444

The proteasome: paradigm of a self-compartmentalizing protease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877444

Structure of 20S proteasome from yeast at 2.4 A resolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877444

Proteasome subunit Rpn1 binds ubiquitin-like protein domains

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877444

Proteasomes and their kin: proteases in the machine age

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877444

Phosphorylation of 20S proteasome alpha subunit C8 (alpha7) stabilizes the 26S proteasome and plays a role in the regulation of proteasome complexes by gamma-interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877444

The ubiquitin-proteasome system and assays to determine responses to inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877444

Proteasome inhibitors: an expanding army attacking a unique target

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877444

Proteasome and peptidase function in MHC-class-I-mediated antigen presentation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877444

Thymoproteasome: probable role in generating positively selecting peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877444

Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877444

Proteasome inhibition as a novel therapeutic target in human cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877444

The proteasome: a novel target for cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877444

Dysfunction of the ubiquitin-proteasome system in multiple disease conditions: therapeutic approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877444

Sent to destroy: the ubiquitin proteasome system regulates cell signaling and protein quality control in cardiovascular development and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877444

Proteasome inhibition during myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877444

The role of proteasome inhibition with bortezomib in the treatment of antibody-mediated rejection after kidney-only or kidney-combined organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877444

Recent advances in proteasome inhibitor discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877444

Proteasome inhibitors: from research tools to drug candidates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877444

Potential for proteasome inhibition in the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877444

Design, synthesis, biological evaluation, and structure-activity relationship (SAR) discussion of dipeptidyl boronate proteasome inhibitors, part I: comprehensive understanding of the SAR of alpha-amino acid boronates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877444

Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877444

Phase II trial of bortezomib for patients with advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877444

A phase II study of bortezomib in the treatment of metastatic malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877444

Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877444

Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877444

Microarray-assisted pathway analysis identifies mitogen-activated protein kinase signaling as a mediator of resistance to the green tea polyphenol epigallocatechin 3-gallate in her-2/neu-overexpressing breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877444

Green tea, black tea and breast cancer risk: a meta-analysis of epidemiological studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877444

Green tea and its catechins inhibit breast cancer xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877444

Inhibition of spontaneous formation of lung tumors and rhabdomyosarcomas in A/J mice by black and green tea.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877444

Synergistic effect of green tea catechins on cell growth and apoptosis induction in gastric carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877444

Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877444

Inhibition of bladder tumor growth by the green tea derivative epigallocatechin-3-gallate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877444

Docking studies and model development of tea polyphenol proteasome inhibitors: applications to rational drug design

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877444

Ester bond-containing tea polyphenols potently inhibit proteasome activity in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877444

Natural polyphenols as proteasome modulators and their role as anti-cancer compounds.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877444

A novel anticancer gold(III) dithiocarbamate compound inhibits the activity of a purified 20S proteasome and 26S proteasome in human breast cancer cell cultures and xenografts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877444

The tumor proteasome as a novel target for gold(III) complexes: implications for breast cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877444

Ni(II), Cu(II), and Zn(II) diethyldithiocarbamate complexes show various activities against the proteasome in breast cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877444

Comparative activities of nickel(II) and zinc(II) complexes of asymmetric [NN'O] ligands as 26S proteasome inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877444

Organic copper complexes as a new class of proteasome inhibitors and apoptosis inducers in human cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877444

Clioquinol and pyrrolidine dithiocarbamate complex with copper to form proteasome inhibitors and apoptosis inducers in human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877444

Metals in anticancer therapy: copper(II) complexes as inhibitors of the 20S proteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877444

Cellular and computational studies of proteasome inhibition and apoptosis induction in human cancer cells by amino acid Schiff base-copper complexes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877444

Salinosporamide A: a highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus salinospora.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877444

Discovery and development of the anticancer agent salinosporamide A (NPI-0052).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877444

Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877444

The proteasome inhibitor NPI-0052 is a more effective inducer of apoptosis than bortezomib in lymphocytes from patients with chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877444

NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877444

Caspase-8 dependent histone acetylation by a novel proteasome inhibitor, NPI-0052: a mechanism for synergy in leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877444

Design, synthesis, and biological evaluation of dibromotyrosine analogues inspired by marine natural products as inhibitors of human prostate cancer proliferation, invasion, and migration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877444

Discovery, design, and synthesis of anti-metastatic lead phenylmethylene hydantoins inspired by marine natural products.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877444

Molecular cloning of fibroblast activation protein alpha, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877444

Hierarchical organization of modularity in metabolic networks

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877444

The large-scale organization of metabolic networks

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877444

Network biology: understanding the cell's functional organization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877444

Reconstruction of metabolic networks from genome data and analysis of their global structure for various organisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877444

Mechanisms of cancer drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877444

Tumour stem cells and drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877444

CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877444

A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877444

Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877444

Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877444

Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877444

Response to bortezomib and activation of osteoblasts in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877444

Identification of genes affecting the toxicity of anti-cancer drug bortezomib by genome-wide screening in S. pombe

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877444

A novel role for a familiar protein in apoptosis induced by proteasome inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877444

Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877444

Nonproteasomal Targets of the Proteasome Inhibitors Bortezomib and Carfilzomib: a Link to Clinical Adverse Events

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877444

Genome-wide siRNA screen for modulators of cell death induced by proteasome inhibitor bortezomib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877444

Argyrin a reveals a critical role for the tumor suppressor protein p27(kip1) in mediating antitumor activities in response to proteasome inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.877444

10.1517/13543776.2014.877444

21 January 2018

Identifiers

DOI

1 reference

6 August 2017

1 reference